



Proventa International's 11th Annual

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS

STRATEGY MEETING WEST COAST USA 2024

📅 Tuesday, 21st May 2024 📍 Hard Rock Hotel San Diego

Assessing, Choosing And Optimizing The Right Set Of Data And Methodologies To Help With Finding Effective Modalities And Techniques For Drug Discovery Biology

BOOK NOW

NEW FOR 2024:

Strategic
Partnerships,
Investment &
Collaborations

Featuring Industry Leaders and Decision Makers:



Adam Mullick
Vice President,
Cardiovascular
Drug Discovery
Ionis Pharma



Amish Patel
Senior Vice President
Technical Operations
**Calidi
Biotherapeutics**



Dimitra Chalkia
Vice President,
Computational
Biology
**Athos
Therapeutics**



Geza Ambrus-Aikelin
Head of Immunology
& Inflammation
**Genesis
Therapeutics**



Igor Nasonkin
Co-founder &
CEO
**Phythera
Therapeutics**



John Leonard
Chief Executive
Officer
**Aeona
Pharmaceuticals**



Stephanie Truhlar
Associate Vice
President
Eli Lilly



20
ROUNDTABLE
DISCUSSIONS



5
TRACKS



2
KEYNOTE
PRESENTATIONS



1
PANEL
DISCUSSION



1
LOCATION



Hard Rock
HOTEL
SAN DIEGO



What Makes
Our Strategy
Meetings
So Unique?

Proud to Partners with:



Dotmatics



Scan to Register



proventainternational.com

UK: +44 (0)208 124 6417
US: +1 (617) 340 2564

✉ info@proventainternational.com

🌐 Proventa International

🐦 @proventaintl

📺 @proventainternational

Proventa International's Strategy Meetings are a completely unique experience.

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS
STRATEGY MEETING WEST COAST USA 2024
Tuesday, 21st May 2024 📍 Hard Rock Hotel San Diego

We're committed to delivering long-term value across our extensive life science network. Through our carefully crafted meetings, collaborative experiences and services Proventa International can offer you the perfect opportunity to meet your business goals, whatever they may be.

Our Vision

To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.

Our Mission

By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.

Our Unique Meeting Format



ROUNDTABLE DISCUSSIONS

These interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.



PERSONALISED AGENDA

Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent is focused and well-utilised.



INNOVATIVE SOLUTIONS

The most effective and time efficient way to assess potential partners at a strategic level. Identify key solution providers that can take your business to the next level and we will help arrange private meetings so you can connect.




STRATEGIC NETWORKING

Strategic networking opportunities form a key benefit of the meeting. Our proven format for building and strengthening alliances to make lasting connections that benefit you.

Seniority of Attendees

- Director Level
- President / VP
- Department Head
- Other
- Team Lead
- C-Level
- Scientist
- Academia
- Manager
- Biology Specialist



Biology

- ✓ Biology
- ✓ R&D
- ✓ Drug Discovery
- ✓ Bioinformatics
- ✓ DMPK
- ✓ ADME
- ✓ Toxicology
- ✓ Structural Biology
- ✓ Pre-Clinical

Bioinformatics

- ✓ CIO
- ✓ Head of Lab
- ✓ Bioinformatics
- ✓ Clinical Data
- ✓ R&D IT
- ✓ Data Sciences
- ✓ Translational Medicine
- ✓ Digital Transformation
- ✓ Omics
- ✓ AI/ML
- ✓ Biostatistics
- ✓ Analytics
- ✓ Genome Informatics
- ✓ Security & Privacy
- ✓ Data Management

Meet Investors

- ✓ Venture Capital
- ✓ Private Equity
- ✓ Large Pharma/Biotech
- ✓ Corporate Venture Capital
- ✓ Institutional
- ✓ High Net Worth
- ✓ Family Office/Private Wealth
- ✓ Government Organisation/
- ✓ Sovereign Wealth Fund
- ✓ Angel

BOOK NOW!

proventainternational.com

UK: +44 (0)208 124 6417
US: +1 (617) 340 2564

info@proventainternational.com
[Proventa International](#)

[@proventaintl](#)
[@proventainternational](#)

PROVENTA
INTERNATIONAL

Facilitator Faculty


**DRUG DISCOVERY BIOLOGY
& BIOINFORMATICS**
STRATEGY MEETING WEST COAST USA 2024
📅 Tuesday, 21st May 2024 📍 Hard Rock Hotel San Diego



Adam Mullick
Vice President,
Cardiovascular Drug
Discovery
Ionis Pharma



Anastasia Velentza
Senior Director,
Head of Discovery
Technology
Plexium



Zev Wisotsky
Director, Drug Discovery
New Modality Solutions
Revvity Signals



Angela Huang
Founder and President
Tempo Bioscience



Amish Patel
Senior Vice President
Technical Operations
Calidi Biotherapeutics



Bishnu Nayak
Senior Director/Site Head
Neologics Bio



Dimitra Chalkia
Vice President,
Computational Biology
Athos Therapeutics



Geza Ambrus-Aikelin
Head of Immunology
& Inflammation
Genesis Therapeutics



Igor Nasonkin
Co-founder & CEO
**Phythera
Therapeutics**



Joan Chen, PhD
Senior Director of
Bioinformatics,
Precision Medicine and
Translational Research
Boundless Bio



John Leonard
Chief Executive Officer
**Aeona
Pharmaceuticals**



Philip Cheung
Founder and
Chief Executive Officer
Refactor Biosciences



Sanjeev Thohan
Scientific Advisory
Board Member
**Cogentis Therapeutics/
Phoenix Molecular
Designs**



Salah Mahmoudi
Co-Founder and Chief
Executive Officer
ReneuBio



Stephanie Truhlar
Associate Vice President
Eli Lilly

BOOK NOW!

proventainternational.com

📞 UK: +44 (0)208 124 6417
US: +1 (617) 340 2564

✉ info@proventainternational.com
🌐 Proventa International

🐦 @proventaintl
🌐 @proventainternational



2024 Sponsors

**DRUG DISCOVERY BIOLOGY
& BIOINFORMATICS**
STRATEGY MEETING WEST COAST USA 2024
📅 Tuesday, 21st May 2024 📍 Hard Rock Hotel San Diego

THOUGHT LEADER



Hammerspace is the data orchestration system that unlocks innovation and opportunity within unstructured data. It orchestrates the data to build new products, uncover new insights, and accelerate time to revenue across industries like AI, scientific discovery, machine learning, extended reality, autonomy, corporate video and more. Hammerspace delivers the world's first and only solution to connect global users with their data and applications on any vendor's data center storage or public cloud services, including AWS, Google Cloud, Microsoft Azure and Seagate Lyve Cloud.

PARTNERING SPONSORS



KEY OPINION LEADER



BOOK NOW!

[proventainternational.com](https://www.proventainternational.com)

📞 UK: +44 (0)208 124 6417
US: +1 (617) 340 2564

✉️ info@proventainternational.com
🌐 Proventa International

🐦 @proventaintl
🌐 @proventainternational



























Agenda at a Glance

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS

STRATEGY MEETING WEST COAST USA 2024

Tuesday, 21st May 2024 Hard Rock Hotel San Diego

	TRACK 1	TRACK 2	TRACK 3	TRACK 4	New TRACK 5
TIME	TARGET IDENTIFICATION & HIT VALIDATION	DMPK / ADME & TOXICOLOGY AND IN VIVO AND IN VITRO PHARMACOLOGY	IN SILICO BIOLOGY / AI & ML	BIOINFORMATICS / DATA INTEGRATION & DATA MINING	STRATEGIC PARTNERSHIPS, INVESTMENT & COLLABORATIONS
PDT					
08:00 - 08:30	BREAKFAST & REGISTRATION				
08:30 - 09:00	OPENING KEYNOTE PRESENTATION: The Enhanced Botanical Drugs for Cancer Therapeutics  PRESENTER: Igor Nasonkin, Co-founder & CEO, Phythera Therapeutics				
09:00 - 10:00	PHARMA/ BIOTECH Navigating the Complexities of Target Identification and Hit Validation in Drug Discovery  Bishnu Nayak, Senior Director/Site Head, Neologics Bio	Optimizing Drug Development: From PK Profiles to Novel Therapeutic Interventions  Sanjeev Thohan, Scientific Advisory Board Member, Cogentis Therapeutics/Phoenix Molecular Designs	Discussing empirical methods in instituting a data-driven drug discovery  Salah Mahmoudi, Co-Founder and Chief Executive Officer, ReneuBio	Advancing drug discovery and new target identification with bioinformatics: opportunities and challenges	Considering contemporary techniques in adapting go-to-market approach  John Leonard, Chief Executive Officer, Aeona Pharmaceuticals
10:00 - 10:05	REFRESHMENT BREAK				
10:05 - 10:25	NETWORKING / 1-1 MEETINGS				
10:25 - 10:45	NETWORKING / 1-1 MEETINGS				
10:45 - 11:05	NETWORKING / 1-1 MEETINGS				
11:10 - 12:10	SOLUTION From Selection to Validation: Exploring Strategies for Target Identification and Validation  Anastasia Velentza, Senior Director, Head of Discovery Technology, Plexium	Integrating breakthroughs in In Silico, In Vivo And In Vitro Pharmacology To Enhance ADMET Modeling SPONSOR	Leveraging AI, target selection technologies/ strategies and infrastructure tools to support computational biology (Topic TBC) DOTMATICS 	Topic TBC HAMMERSPACE 	Harnessing the Power of Data: Integrating Bioinformatics, Chemistry Informatics, and AI for Next-Generation Solutions  Zev Wisotsky, PhD, Director, Drug Discovery New Modality Solutions, Revvity Signals REVVITY SIGNALS 
12:15 - 13:15	PHARMA/ BIOTECH Enumerating Criteria Selection Of Appropriate Modalities And Hit ID Strategies For First In Class Targets (Topic TBC)  Adam Mullick, Vice President, Cardiovascular Drug Discovery, Ionis Pharma	Drug target validation during discovery and preclinical development stages: What, Why and How  Yuhua Ji, VP of Drug Discovery, Grace Science	Evaluating practical uses of latest AI/ML tools to expedite and increase efficiency in drug discovery process  Stephanie Truhlar, Associate Vice President, Eli Lilly	Setting fundamentals in data democratization and the factors to consider in making it happen  Philip Cheung, Founder and Chief Executive Officer, Refactor Biosciences	Leveraging on academic partnerships to further drug discovery and development operations  Amish Patel, Senior Vice President Technical Operations, Calidi Biotherapeutics
13:15 - 14:00	NETWORKING LUNCH				
14:00 - 14:20	NETWORKING / 1-1 MEETINGS				
14:20 - 14:40	NETWORKING / 1-1 MEETINGS				
14:40 - 15:10	AFTERNOON KEYNOTE PRESENTATION  HAMMERSPACE DATA IN MOTION				
15:10 - 16:10	PHARMA/ BIOTECH Target validation and small molecule hit identification in the era of modern drug discovery  Geza Ambrus-Aikelin, Head of Immunology & Inflammation, Genesis Therapeutics	Latest approaches and trends for improving nonclinical studies  Angela Huang, Founder and President, Tempo Bioscience	Navigating the latest machine learning tools for in-silico drug discovery and its contribution in accelerating drug discovery process  Dimitra Chalkia, Vice President, Computational Biology, Athos Therapeutics	Introducing cutting-edge bioinformatics applications in novel therapeutic areas  Joan Chen, PhD, Senior Director of Bioinformatics, Precision Medicine and Translational Research, Boundless Bio	What are some of the effective ways to initiate financial strategies using the go-to-fundraising model
16:10 - 16:30	AFTERNOON REFRESHMENT BREAK				
16:30 - 17:00	PANEL DISCUSSION: Tackling the pros and cons of different financing blueprint: go-to-clinic vs go-to-market vs go-to-fundraising strategies and the criteria to determine which program an organization can adapt  PANELIST: Sanjeev Thohan, Scientific Advisory Board Member, Cogentis Therapeutics/Phoenix Molecular Designs  PANELIST: Philip Cheung, Chief Executive Officer, Refactor Biosciences				
17:00 - 18:00	DRINKS & CANAPES RECEPTION				

Event Day | Keynote Presentations

A great way to open the roundtable discussions is through a timely presentation from a top-tier biotech/pharmaceutical company. Listen as we hear this 30-minute exposition on this meeting's pressing topic.

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS

STRATEGY MEETING WEST COAST USA 2024

Tuesday, 21st May 2024 Hard Rock Hotel San Diego



08:30 - 09:00 PT

OPENING KEYNOTE PRESENTATION

Accelerate Drug Discovery Research Through Different Modalities



Igor Nasonkin
Co-founder & CEO
Phythera Therapeutics

ABOUT THE SPEAKER

Igor Nasonkin is a Founder, Director, and Principal Investigator, with 9 years in industry (Phythera Therapeutics, Lineage Cell Therapeutics, Biotime, Bresagen) and 24 years in academia (UPitt, NIH, JHU, MIT, UM, UBC). He specialized in small molecule-based therapies modulating neurodegenerative diseases and cancer, botanical-based drugs for cancer therapeutics, cell & gene therapies (retina, brain), stem cell-based therapies, and building new projects and teams from the ground up. Igor has extensive experience in building and leading several productive & cohesive research teams, conceptualizing new ideas and research directions, grant writing (NIH, DOD, CIRM, foundation grants), manuscript writing, drafting patent applications, sponsored projects agreements, and business plans. He has written for a variety of Scientific reviewers (several journals), while being a member of the Editorial Board (several journals). His successfully funded SBIR grants include: 5R44EY027654 09/30/2017-5/31/2019; 3 R44 EY 027654-02 S1 06/01/2019-05/31/2020

14:40 - 15:10 PT

AFTERNOON KEYNOTE PRESENTATION

Topic TBC



Speaker TBC



ABOUT THE SPEAKER

Speaker TBC

16:30 - 17:00 PT

AFTERNOON KEYNOTE PRESENTATION

Tackling the pros and cons of different financing blueprint: go-to-clinic vs go-to-market vs go-to-fundraising strategies and the criteria to determine which program an organization can adapt



PANEL

Sanjeev Thohan
Scientific Advisory Board Member
Cogentis Therapeutics/
Phoenix Molecular Designs



PANEL

Philip Cheung
Founder and Chief Executive Officer
Refactor Biosciences

ABOUT THE SPEAKER

Sanjeev is currently the President of SARx Consulting after 25 years in industry his practice encompasses Fractional Leadership of R&D activities from Lead Optimization to IND filing and clinical trial design. He is also a SME for clinical biomarker prosecution, and translational mechanistic studies as they relate to clinical trials. He personally generated and overseen programs for both small molecules and antibody drug conjugates (ADC) in the Anti-viral, Anti-infective, Anti-inflammatory, Biodefense, Cardiovascular/ Metabolic and Oncology, therapeutic areas. He is an active mentor and fundraiser for startups as well as a Scientific Advisory Board member and founder of several innovative companies.

BOOK NOW!

proventainternational.com



UK: +44 (0)208 124 6417
US: +1 (617) 340 2564



info@proventainternational.com



Proventa International



@proventaintl



@proventainternational



Event Day

TRACK 1 Target Identification & Hit Validation

Improving efficiency in finding novel therapeutic targets continues to be an immediate priority and hurdle in the pharma and biotech industry. This track aims to explore the undruggable space for utilizing AI/ML, optimizing target identification pathways and many more. How can we ensure the next druggable target frontier stays viable?

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS

STRATEGY MEETING WEST COAST USA 2024

Tuesday, 21st May 2024 Hard Rock Hotel San Diego

08:00 - 08:30 PT BREAKFAST & REGISTRATION

08:30 - 09:00 PT OPENING KEYNOTE PRESENTATION
[See Page 6](#)

09:00 - 10:00 PT ROUNDTABLE 1

Navigating the Complexities of Target Identification and Hit Validation in Drug Discovery

- Lack of Understanding of Disease Mechanisms
- Role of AI in Target identification and Validation
- Target Druggability and Limitation of Predictive Model
- Biological Variability and Therapeutic Validation



Bishnu Nayak
Senior Director/Site Head
Ionis Pharma

ABOUT THE SPEAKER

Bishnu is an immunologist by training with more than 15-years of experience in drug discovery research. His expertise include target identification, validation, translational research, MoA studies, and validation of therapeutic concepts, both in vitro and in vivo. He worked extensively with small molecules and biologics, particularly in immuno-oncology and inflammation space. From target discovery to lead identification and preclinical validation, he contributed at large pharmaceutical companies like Novartis and AbbVie (Pharmacyclics), medium-sized firms like AnaptysBio, and small biotechs like HealthTell and NeologicsBio. Currently, he serves as Senior Director and Site Head at Neologics Bioscience, San Diego.

10:00 - 11:05 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 PT ROUNDTABLE 2

From Selection to Validation: Exploring Strategies for Target Identification and Validation

- Strategies and methods for target selection
- Criteria for target selection
- Target validation: strategies and methods to demonstrate potential of target therapeutic benefit
- Hit finding approaches for new targets



Anastasia Velentza
Senior Director, Head of Discovery Technology
Plexium

ABOUT THE SPEAKER

Anastasia Velentza is the Founder of AVeNew Insights LLC, drug discovery business consulting and services. Previously, she was the Head of Discovery Technology at Plexium, a TPD company. Anastasia has 23 years in Drug Discovery, with expertise in Discovery Biology and Molecular Pharmacology across multiple therapeutic areas, modalities and targets. Before Plexium, she held positions of increasing responsibility at Novartis, Dart Neuroscience and Ferring Pharmaceuticals. Anastasia was NIH Research Award scholar in a drug discovery training program at Northwestern University in Chicago, IL. She earned her Bachelor of Science in Chemistry at the University of Patras in Greece, and a Ph.D. from the same institution in Bioorganic Chemistry, funded by a competitive scholarship and EU programs.

12:15 - 13:15 PT ROUNDTABLE 3

Enumerating Criteria Selection Of Appropriate Modalities And Hit ID Strategies For First In Class Targets (Topic TBC)



Adam Mullick
Vice President, Cardiovascular Drug Discovery
Ionis Pharma

ABOUT THE SPEAKER

Speaker TBC

13:15 - 14:40 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 PT AFTERNOON KEYNOTE PRESENTATION
[See Page 6](#)

15:10 - 16:10 PT ROUNDTABLE 4

Target validation and small molecule hit identification in the era of modern drug discovery

- Levels of target validation (genetic, cellular, animal models, clinical validation)
- Virtual screening approaches and the impact of AI on hit ID
- Small molecule libraries and their pros and cons for screening (covalent, focused, DEL, macrocycle, natural product etc)
- Popular hit ID approaches (HTRF, MS, nanoBRET, reporter cell lines, etc)
- Hit ID, hit confirmation and hit validation criteria



Geza Ambrus-Aikelin
Head of Immunology & Inflammation
Genesis Therapeutics

ABOUT THE SPEAKER

Since completing his postdoctoral studies at The Scripps Research Institute, Geza Ambrus-Aikelin has been pursuing preclinical drug discovery and development of small molecules in the immunology, oncology and metabolic therapeutic areas. Initially working at the large pharmaceutical companies of Takeda and Johnson & Johnson, he transitioned into biotech where he contributed to progressing 2 candidates into the clinic and witnessed the successful acquisitions of Jecure Therapeutics by Genentech and Vividion Therapeutics by Bayer. He is currently leading an immunology program at Odyssey Therapeutics.

16:10 - 16:30 PT AFTERNOON REFRESHMENT BREAK

16:30 - 17:00 PT PANEL DISCUSSION
[See Page 6](#)

17:00 - 18:00 PT DRINKS & CANAPES RECEPTION

BOOK NOW!

proventainternational.com

UK: +44 (0)208 124 6417
US: +1 (617) 340 2564

info@proventainternational.com
Proventa International

@proventaintl
@proventainternational



Event Day

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS

STRATEGY MEETING WEST COAST USA 2024

Tuesday, 21st May 2024 Hard Rock Hotel San Diego

TRACK 2 DMPK / ADME & Toxicology and In Vivo and In Vitro Pharmacology

A key idea in biology is that structure, to a large extent, dictates function. The rapid development of sensitive biophysical methods and emerging technologies that interrogate compound properties and mechanisms of action is transforming drug discovery.

08:00 - 08:30 PT BREAKFAST & REGISTRATION

08:30 - 09:00 PT OPENING KEYNOTE PRESENTATION
[See Page 6](#)

09:00 - 10:00 PT ROUNDTABLE 1

Optimizing Drug Development: From PK Profiles to Novel Therapeutic Interventions

- Is there an ideal PK profile
- PKPD models and their translatability
- Leveraging AI in the ADME space
- How do we tackle novel mechanisms for therapeutic interventions.



Sanjeev Thohan
Scientific Advisory Board Member
Cogentis Therapeutics/Phoenix Molecular Designs

ABOUT THE SPEAKER
[See Page 6](#)

10:00 - 11:05 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 PT SOLUTION FOCUS ROUNDTABLE 2

Integrating breakthroughs in In Silico, In Vivo And In Vitro Pharmacology To Enhance ADMET Modeling



Speaker TBC

ABOUT THE SPEAKER
Speaker TBC

12:15 - 13:15 PT ROUNDTABLE 3

Drug target validation during discovery and preclinical development stages: What, Why and How

- What is target validation and what does it mean in discovery?
- Why is the target validation necessary after the target identification and when should it be initiated?
- What are techniques for drug target validation?
- What are main challenges associated with first-in-class drug discovery target validation?



Yuhua Ji
VP of Drug Discovery
Grace Science

ABOUT THE SPEAKER

Yuhua Ji, Ph.D, has broad experiences in drug discovery and development. She has a proven track record of building team from the ground up. She led and contributed to over ten development candidates and IND-filings. Dr. Ji has extensive expertise in medicinal chemistry, CMC and preclinical development of small molecules. She is the principal inventor of revefenacin and named as the inventor on over 100 patents and the author of over 20 publications. Currently, she is VP of drug discovery at Grace Science. Previously, Dr Ji was the head of Medicinal Chemistry at Zai Lab and IND director at Virogen Biotech. During her years at Path, She led discovery chemistry and CMC, and supported several clinical development programs. She led the discovery and early development of YUPELRITM at Theravance

13:15 - 14:40 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 PT AFTERNOON KEYNOTE PRESENTATION
[See Page 6](#)

15:10 - 16:10 PT ROUNDTABLE 4

Latest approaches and trends for improving nonclinical studies

- Identifying appropriate human cell based models in 2D or 3D/organoids for preclinical studies;
- Identifying the rein of using animal models in pre-clinical testing and combining current in vitro technique to achieve desired result;
- What are the latest biomarker studies that can be utilized for complex diseases?
- Evaluating complex human cell based models and MicroPhysiological Systems (MPS) in combination with other techniques to address the problem of heterogeneous diseased population;
- Anticipating the future of In vivo and In vitro pharmacology for diseases such as cancer, neurodegeneration, and rare diseases



Angela L. Huang
Founder and President
Tempo Bioscience

ABOUT THE SPEAKER

Tempo Bioscience focuses on developing human stem cell (human iPSC technology) based 2D&3D cell models and biosensor-incorporated platform technologies for the biotech-pharmaceutical industry. Angela is listed as an inventor on numerous patents and has published in journals such as Nature. She received her scientific training from University of California, Berkeley, University of California, San Diego, and University of California, San Francisco.

16:10 - 16:30 PT AFTERNOON REFRESHMENT BREAK

16:30 - 17:00 PT PANEL DISCUSSION
[See Page 6](#)

17:00 - 18:00 PT DRINKS & CANAPES RECEPTION

BOOK NOW!

proventainternational.com

UK: +44 (0)208 124 6417
US: +1 (617) 340 2564

info@proventainternational.com
Proventa International

@proventaintl
@proventainternational



Event Day

TRACK 3 In Silico Biology / AI & ML

The utility of computational methods is widely used in various stages of drug discovery and development. From aiding target ID & validation, limiting the use of animal models in pharmacology to aiding rational drug design, this track will explore novel approaches and application of in silico techniques to maximize productivity towards clinical success.

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS

STRATEGY MEETING WEST COAST USA 2024

Tuesday, 21st May 2024 Hard Rock Hotel San Diego

08:00 - 08:30 PT BREAKFAST & REGISTRATION

08:30 - 09:00 PT OPENING KEYNOTE PRESENTATION

[See Page 6](#)

09:00 - 10:00 PT ROUNDTABLE 1

Discussing empirical methods in instituting a data-driven drug discovery



- Data reliability: ensuring that data collected is accurate, consistent, and free from errors. Garbage in, garbage out.
- Analysis complexity: Managing and making sense of vast and intricate datasets to extract valuable insights and patterns relevant to drug discovery.
- Integration challenges: Integrating diverse data sources, including genomics, proteomics, metabolomics, clinical records, and imaging data.
- Resource allocation: How much resources need to be dedicated to maximize and accelerate the drug discovery process? Can everyone do it?



Salah Mahmoudi
Co-Founder and Chief Executive Officer,
ReneuBio

ABOUT THE SPEAKER

Dr. Salah Mahmoudi boasts over two decades of expertise in life science R&D, having led multidisciplinary research and drug discovery teams at prestigious institutions such as Stanford University, Pfizer, and Alkahest. His specialization lies in target identification, validation, and preclinical drug development, driving numerous successful initiatives in the field. Dr. Mahmoudi's entrepreneurial spirit led him to co-found NoraChem, where he harnessed generative AI for innovative small molecule design. Currently serving as a scientific advisor for Norachem, NeuroAge, and Level 42 AI, he now channels his experience and leadership skills as CEO and co-founder of ReneuBio, pioneering transformative treatments for devastating age-related neurological diseases.

10:00 - 11:05 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 PT SOLUTION FOCUS ROUNDTABLE 2

Leveraging AI, target selection technologies/ strategies and infrastructure tools to support computational biology (Topic TBC)



Speaker TBC

Dotmatics

ABOUT THE SPEAKER

Speaker TBC

12:15 - 13:15 PT ROUNDTABLE 3

Evaluating practical uses of latest AI/ML tools to expedite and increase efficiency in drug discovery process



Stephanie Truhlar
Associate Vice President
Eli Lilly

- What applications are big wins for ML/AI in drug discovery? Success stories to date
- What are emerging as best practices for integrating ML/AI in drug discovery workflows?
- What do you see as the major barriers/hurdles in applying ML/AI?
- How to quickly adapt to the rapidly evolving ML/AI landscape?

ABOUT THE SPEAKER

Stephanie Truhlar received her Ph.D. from the University of California, San Francisco and completed her post-doctoral training at the University of California, San Diego. In her 16 years at Eli Lilly and Company, she has engineered numerous clinical candidates and developed a proprietary bispecific antibody platform. Stephanie has numerous awards in both the academic and pharmaceutical sectors, is a co-inventor on seven patents, and has presented numerous external talks and peer-reviewed publications. Stephanie leads the Computational Sciences and Protein Engineering group in Biotechnology Discovery Research, where she is responsible for the discovery of protein and antibody therapeutics and applying ML/AI to design and optimization of biotherapeutics.

13:15 - 14:40 PT NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 PT AFTERNOON KEYNOTE PRESENTATION

[See Page 6](#)

15:10 - 16:10 PT ROUNDTABLE 4

Navigating the latest machine learning tools for in-silico drug discovery and its contribution in accelerating drug discovery process



Dimitra Chalkia
Vice President, Computational Biology
Athos Therapeutics

ABOUT THE SPEAKER

Speaker TBC

16:10 - 16:30 PT AFTERNOON REFRESHMENT BREAK

16:30 - 17:00 PT PANEL DISCUSSION

[See Page 6](#)

17:00 - 18:00 PT DRINKS & CANAPES RECEPTION

BOOK NOW!

proventainternational.com

UK: +44 (0)208 124 6417
US: +1 (617) 340 2564

info@proventainternational.com
Proventa International

@proventaintl
@proventainternational

PROVENTA
INTERNATIONAL

Event Day

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS

STRATEGY MEETING WEST COAST USA 2024

Tuesday, 21st May 2024 Hard Rock Hotel San Diego

TRACK 4 Bioinformatics / Data Integration & Data Mining

The pharma and biotech sector continues to seek ways to address challenges in R&D productivity, spending cuts and volatile market conditions. Strategic partnerships and alliances have grown in importance to reduce cost, share risks and rewards while maximizing learning opportunities resulting from successful collaborations.

08:00 - 08:30 PT BREAKFAST & REGISTRATION

08:30 - 09:00 PT OPENING KEYNOTE PRESENTATION
[See Page 6](#)

09:00 - 10:00 PT ROUNDTABLE 1

Advancing drug discovery and new target identification with bioinformatics: opportunities and challenges



Jay Chung
Associate Director of Bioinformatics
Plexium

ABOUT THE SPEAKER
Speaker TBC

10:00 - 11:05 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 PT SOLUTION FOCUS ROUNDTABLE 2

Topic TBC



Speaker TBC



ABOUT THE SPEAKER
Speaker TBC

12:15 - 13:15 PT ROUNDTABLE 3

Setting fundamentals in data democratization and the factors to consider in making it happen

- **Accessibility and Usability:** Addressing how to make complex bioinformatics data comprehensible and useful to a broad range of users without specialized training.
- **Privacy and Security Concerns:** Ensuring that data democratization does not compromise the privacy of data subjects or the security of the data itself.
- **Data Quality and Standardization:** Implementing rigorous standards to ensure data integrity and comparability across different datasets and sources.
- **Technological Infrastructure:** Discussing the technological requirements and challenges in setting up systems that can handle large-scale data sharing and analysis.
- **Bridging Discovery with Development:** Highlighting the need for effective translational bioinformatics to ensure that clinical data informs earlier stages of discovery, enhancing understanding of mechanisms, pathways, patient stratifications, and biomarker discovery.
- **Ethical and Regulatory Issues:** Considering the ethical implications and regulatory requirements in sharing and utilizing bioinformatics data.



Philip Cheung
Founder and Chief Executive Officer
Refactor Biosciences

ABOUT THE SPEAKER

Phil Cheung brings over two decades of expertise in pharmaceutical research, specializing in scientific computing and software development. He founded Refactor Biosciences and Juva Health, focusing on novel therapies for rare diseases and migraines, respectively. Previously, Phil led the computational biology group at Dart NeuroScience, significantly advancing their target discovery pipeline. His tenure at Pfizer saw him develop a drug repositioning platform using machine learning. Phil advises various biotechs and serves on boards of tech companies, applying his knowledge to improve scientific outcomes and patient care. His work is marked by several patents in data analysis and clinical testing systems.

13:15 - 14:40 PT NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 PT AFTERNOON KEYNOTE PRESENTATION
[See Page 6](#)

15:10 - 16:10 PT ROUNDTABLE 4

Introducing cutting-edge bioinformatics applications in novel therapeutic areas

- **Discovery, AI-aided compound design** – challenges
- **AI/ML to predict drug response** – what are the challenges in modeling?
- **PM for patient selection based on mutation, amplification status** – who to select for, who to select against?
- **Digital pathology** – a long way to go and what are the technical challenges?



Joan Chen
Senior Director of Bioinformatics,
Precision Medicine and Translational Research
Boundless Bio

ABOUT THE SPEAKER

Joan Chen, PhD, has over 16 years of experience in the biopharma industry, with a focus on oncology for the past ten years. She has led many drug discovery, translational research programs and helped advance a number of drug candidates from preclinical research into the clinical trials. Dr. Chen's expertise in drug development includes target identification and validation, designing studies for mechanisms of action, pharmacodynamic response (both preclinical and clinical), machine learning and NGS data analysis in biomarker discoveries, generating disease hypotheses for patient selections in clinical trials. Dr. Chen holds a PhD in Molecular, Cell and Development Biology with a specialization in bioinformatics from UCLA. She was a Bioinformatics Senior Scientist at eFFECTOR Therapeutics; Director of Bioinformatics at Certis Oncology; Research Fellow at Turning Point Therapeutics (acquired by BMS in 2022), and currently Senior Director at Boundless Bio.

16:10 - 16:30 PT AFTERNOON REFRESHMENT BREAK

16:30 - 17:00 PT PANEL DISCUSSION
[See Page 6](#)

17:00 - 18:00 PT DRINKS & CANAPES RECEPTION

BOOK NOW!

proventainternational.com

UK: +44 (0)208 124 6417
US: +1 (617) 340 2564

info@proventainternational.com
Proventa International

@proventaintl
@proventainternational





Event Day

TRACK 5

Strategic Partnerships, Investment & Collaborations

Bringing together Managing Partners & C-level executives from investment firms supporting innovation in the clinical trial process, strategies from pharma companies and corporate arms with a vested interest in driving this innovation. It comes with the purpose of identifying and collaborating with potential drug development partners whilst addressing industry challenges in this area

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS

STRATEGY MEETING WEST COAST USA 2024

Tuesday, 21st May 2024 Hard Rock Hotel San Diego



09:00 - 10:00 PT

ROUNDTABLE 1

Considering contemporary techniques in adapting go-to-market approach



- Understand your strengths and weaknesses
 - Complementarities
 - Common Goals
 - Compatibility
 - Change
- Establish the business goals for partnership
- Develop objectives
- Dedicated function or engaging a consulting group?



John Leonard
Chief Executive Officer
Aeona Pharmaceuticals

ABOUT THE SPEAKER

Speaker TBC



11:10 - 12:10 PT

SOLUTION FOCUS ROUNDTABLE 2

Harnessing the Power of Data: Integrating Bioinformatics, Chemistry Informatics, and AI for Next-Generation Solutions



- Data Wrangling: Best practices and tools for bioinformatics and chemistry informatics data integration and quality control.
- AI-Driven Innovation: Leveraging integrated data with AI and machine learning for drug discovery and personalized medicine.
- Embracing AI: Practical steps for companies to adopt AI and data-driven approaches, including infrastructure and talent



Zev Wisotsky
Director, Drug Discovery
New Modality Solutions
Revvity Signals

revvity
signals

ABOUT THE SPEAKER

Zev Wisotsky is Director, Drug Discovery New Modality Solutions at Revvity Signals. Zev has 10+ years experience supporting Pharma and Biotech informatics and data strategies. He has a Ph.D. in Neuroscience from University of California Riverside.



12:15 - 13:15 PT

ROUNDTABLE 3

Leveraging on academic partnerships to further drug discovery and development operations



- Academic and non profit organizations are at the forefront of cutting edge scientific research, often conducting groundbreaking studies in various fields.
- Academic and non profit often have state-of-the-art facilities and specialized equipment that may cost millions of \$ and not available to biotechnology companies
- Academic and non profit partnerships can facilitate collaboration on preclinical and physician sponsored clinical studies
- Academic and non profit partnerships provide an opportunity to identify and recruit talented researchers and students who can contribute to drug discovery and development operations for the future.
- Tech transfer office for Intellectual property and licensing opportunities
- extensive experience in licensing and out licensing several technologies from Academia and non profit organizations and even commercialized such asset



Amish Patel
Senior Vice President Technical Operations
Calidi Biotherapeutics

ABOUT THE SPEAKER

Dr. Amish Patel has over 20 years of leadership experience in the global biotech industry, providing strategic guidance throughout the entire biologic product life-cycle and been involved with fifteen+ INDs and commercial product launch. Dr. Patel is responsible for oversight of Global Manufacturing, Quality Control, Quality Assurance and Supply Chain to produce Clinical and Commercial cancer therapies utilizing Calidi's innovative oncolytic viral therapies with stem cell-based delivery platforms to treat cancers with significant unmet needs. Dr. Patel has managed the CDMO network and supplied clinical products for phase 1 and phase 3 trials globally. Dr. Patel has extensive experience in licensing and out licensing several technologies from Academia and non profit organizations and even commercialized such assets. He serves as Technical Activities Committee of the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) part of Manufacturing USA* and funded through the U.S. Department of Commerce with significant additional support from its members. He was most recently, the Senior Director of Product Development at Emergent BioSolutions (formerly PaxVax, Inc., prior to acquisition), where he successfully built and directed cross-functional teams working on numerous biologic Clinical and commercial products.



15:10 - 16:10 PT

ROUNDTABLE 4

What are some of the effective ways to initiate financial strategies using the go-to-fundraising model



Speaker TBC

ABOUT THE SPEAKER

Speaker TBC

BOOK NOW!

proventainternational.com



UK: +44 (0)208 124 6417
US: +1 (617) 340 2564



info@proventainternational.com



Proventa International




@proventaintl



@proventainternational





Pharma FEATURES

**Find your new partner,
explore our digital storefronts**

www.pharmafeatures.com



Contact us to discuss how we can help generate
growth for your business

Dex Marco Guibelondo

*Marketing Content Writer, Proventa International
Editor-in-Chief, PharmaFEATURES*

dex@proventainternational.com

DRUG DISCOVERY BIOLOGY & BIOINFORMATICS STRATEGY MEETING WEST COAST USA 2024

Tuesday 21st May 2024 📍 Hard Rock Hotel San Diego

**Delegate
Price**

\$699

*Pharma/Biotech/
Academia

**Vendor/
Service
Provider**

\$2999



OUR FACE TO FACE MEETING IN MAY 2024

**STRATEGY
MEETING
EAST COAST USA**

📍 Hyatt Regency
Princeton

MAY 14

**DRUG DISCOVERY BIOLOGY
& BIOINFORMATICS**
STRATEGY MEETING EAST COAST USA 2024

MAY 15

**MEDICINAL
CHEMISTRY**
STRATEGY MEETING
EAST COAST USA 2024

MAY 16

**CLINICAL OPERATIONS &
CLINICAL TRIAL SUPPLY CHAIN**
STRATEGY MEETING EAST COAST USA 2024

**STRATEGY
MEETING
WEST COAST USA**

📍 Hard Rock Hotel
San Diego

MAY 21

**DRUG DISCOVERY BIOLOGY
& BIOINFORMATICS**
STRATEGY MEETING WEST COAST USA 2024

MAY 22

**MEDICINAL
CHEMISTRY**
STRATEGY MEETING
WEST COAST USA 2024

MAY 23

**CLINICAL OPERATIONS &
CLINICAL TRIAL SUPPLY CHAIN**
STRATEGY MEETING WEST COAST USA 2024

Hotel & Venue



SAN DIEGO

Hard Rock Hotel San Diego

You're the main act in San Diego. At Hard Rock Hotel, we immerse you in our musical amenities, world-class service, and intoxicating location in downtown San Diego. Tour the Gaslamp Quarter on an Electra bike and walk a block to Petco Park.

BOOK NOW!

We only have limited rooms available!

[Hotel Details >](#)

[Map & Directions >](#)



Visit us on our website to know
more about our meetings

www.proventainternational.com